《蓝筹业绩》石药(01093.HK)全年纯利51.6亿人币升38.9% 派末期息9港仙
石药集团(01093.HK)公布截至去年12月底止全年业绩,营业额249.42亿元人民币(下同),按年升12.8%。纯利51.6亿元,按年升38.9%;每股盈利43.16分。派末期息9港仙。
期内,毛利为186.85亿元,按年升17.4%;毛利率升2.9个百分点至74.9%。按业务划分,去年成药收入204.05亿元,按年升13.8%;维生素C收入18.59亿元,跌3.2%;抗生素收入升30.4%至13.73亿元。
於去年,研发费用为28.9亿元,按年增加44.5%,约占成药业务收入的14.2%。
集团指,目前在研项目约300项,其中小分子创新药40余项、大分子创新药40余项,新型制剂20余项,主要聚焦在肿瘤、自身免疫、精神神经、消化和代谢、心脑血管系统及抗感染治疗领域。目前有30个药品处於注册审评待批阶段,41个产品正在开展临床试验(包括30个创新药以及11个新型制剂),8个产品正在进行生物等效试验,以及2个产品待批临床批件。(ek/a)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.